Rifamycin MMX Shows Minimal Impact on Gut Resistome in Cirrhosis, Trends Towards Reduced Vancomycin Resistance
What the Researchers Tested
This study utilized shotgun metagenomic sequencing to analyze the gut resistome in patients with compensated cirrhosis. Participants were randomized into two groups: 15 received rifamycin SV MMX (RiVM) and 15 received placebo for 30 days. Gut microbial DNA was extracted from stool samples collected before and after the treatment period. The sequencing data was then processed to identify and quantify antibiotic resistance genes using the Comprehensive Antibiotic Resistance Database (CARD) for annotation. The research employed a combination of univariable and multivariable statistical methods, including LEfSe, paired-Wilcoxon testing, and MaAsLin3, to assess longitudinal changes in the resistome. Machine learning (ML) models were also deployed to evaluate ARG changes at both individual subject and group levels, aiming to discern subtle shifts that traditional statistical methods might overlook. The primary objective was to determine if RiVM, a rifamycin derivative, contributes to the expansion of ARGs, a concern previously raised by preclinical data regarding rifaximin.
What the Study Found
Rifamycin SV MMX (RiVM) induced minimal perturbation of the gut resistome, with no significant increase in antibiotic resistance genes (ARGs) observed after 30 days of therapy compared to placebo following FDR adjustment.
Univariable and multivariable analyses identified a trend towards lower vancomycin resistance-associated ARGs, specifically vanW and vanT operon-associated genes, after RiVM exposure.
Nominal increases in several Enterobacteriaceae-associated multidrug efflux regulators (e.g., evgS, emrK, mdtA) were noted post-rifamycin, but these did not maintain statistical significance after FDR correction.
Group-level machine learning models showed limited discrimination between RiVM and placebo groups for overall ARG changes, although within-subject longitudinal models demonstrated improved classification performance.
No increase in infections or treatment-related safety concerns were observed in the RiVM group during the 30-day trial period.
Why This Matters to Clinical Practice
The proliferation of antibiotic resistance genes (ARGs) in the gut microbiome is a critical concern in patients with liver cirrhosis, as it is associated with increased morbidity, higher rates of hospitalization, and poorer clinical outcomes. Patients with cirrhosis frequently require antibiotic courses, making them particularly vulnerable to resistome changes. Understanding the impact of commonly used medications, such as rifamycins for hepatic encephalopathy, on the gut resistome is therefore paramount for guiding clinical practice and mitigating the global challenge of antimicrobial resistance. This study provides crucial evidence suggesting that rifamycin MMX, over a 30-day course, does not significantly contribute to the expansion of gut ARGs in compensated cirrhosis. This finding is reassuring for clinicians who rely on rifamycins for managing complications of cirrhosis, as it alleviates concerns about exacerbating antibiotic resistance. The observed trend towards reduced vancomycin resistance, if validated in larger cohorts, could represent a significant clinical advantage, offering a potential strategy to modulate the resistome positively in a high-risk population.
Clinical & Workflow Takeaways
For practicing hepatologists and gastroenterologists managing patients with compensated cirrhosis, these findings are largely reassuring. The data suggest that the 30-day use of rifamycin SV MMX for indications such as hepatic encephalopathy is unlikely to significantly exacerbate the gut resistome, a critical consideration given the high burden of infection and antibiotic use in this population. Clinicians should continue to use rifamycin MMX as per established guidelines, with reduced concern regarding its contribution to overall ARG expansion. Furthermore, the intriguing signal of reduced vancomycin resistance warrants further investigation in larger, longer-term studies, as this could potentially lead to strategies for resistome modulation. However, vigilance for any potential shifts in specific resistance gene profiles, even those not reaching statistical significance in this small trial, remains prudent.
Limitations and What Remains Uncertain
The primary limitation of this study is its small sample size (n=30) and relatively short duration (30 days) of intervention, which may limit the generalizability and power to detect subtle or long-term changes in the gut resistome. While the study was double-blind and placebo-controlled, the small cohort may not fully represent the heterogeneity of patients with compensated cirrhosis. The observed 'trends' towards reduced vancomycin resistance and nominal increases in certain efflux regulators did not withstand FDR adjustment, indicating they should be interpreted with caution and require confirmation in larger, adequately powered trials. The study also focused on compensated cirrhosis, and its findings may not be directly applicable to patients with decompensated disease, who often have more profound gut dysbiosis and a higher risk of infection and antibiotic exposure. Future research should also explore the functional implications of these resistome changes on actual clinical outcomes, such as rates of infection with resistant organisms.
Explore the Work Behind Clinical AI
MedXchange Research Fellowship
Publish Clinical AI Research With Us
Our 10-week fellowship mentors physicians and researchers to build foundation models, analyze multimodal health datasets, and co-author peer-reviewed clinical studies.
Related Clinical AI Stories
AI's Role in Diagnosing Rare and Undiagnosed Diseases: A Critical Perspective
A recent perspective from the NEJM Catalyst Insights Council highlights the significant potential of artificial intelligence (AI) in accelerating the diagnosis of rare and undiagnosed diseases. These conditions, often individually uncommon, collectively affect a substantial patient population, leading to prolonged diagnostic odysseys, increased healthcare costs, and significant patient morbidity. The Council emphasizes that while AI offers unprecedented capabilities in pattern recognition across vast datasets, it represents only one component of a multifaceted solution required to address this complex clinical challenge. The editorial underscores that the inherent complexity of rare diseases—characterized by phenotypic heterogeneity, genetic variability, and limited epidemiological data—makes them particularly amenable to AI's strengths in identifying subtle correlations and anomalies. However, achieving accurate and timely diagnoses will necessitate more than just technological advancements; it demands integrated strategies encompassing robust data infrastructure, multidisciplinary clinical collaboration, and careful consideration of ethical implications.
LLM Chatbot Offers Promising, Yet Flawed, Allergen Avoidance Guidance in Contact Dermatitis
A recent quantitative evaluation study explored the utility of a Large Language Model (LLM) chatbot, specifically GPT-4, in providing allergen-free product recommendations for patients with contact dermatitis. The study assessed the LLM's ability to recommend products free of 30 common allergen groups found in international standard patch tests. While the chatbot demonstrated a high proportion of valid responses, particularly for cosmetics and medications, clinicians must recognize its limitations, especially concerning complex allergens prone to cross-reactivity. Over a period from September 2023 to January 2024, GPT-4 was prompted to suggest five allergen-free products for each allergen group, utilizing three distinct question formats. Dermatologists manually reviewed and categorized 2250 responses for validity, invalidity, cross-reactions, unknown status, and unresponsiveness. The findings indicate a significant potential for LLM tools to assist in allergen avoidance counseling, albeit with a crucial need for human verification and oversight.
LLM Performance in PMOS/PCOS Information: DeepSeek-V4 Outperforms GPT-5.5 and Gemini 3.5 in Clinician-Rated Quality and Empathy
A recent study evaluated the information quality, readability, transparency, and perceived empathy of responses from three widely accessible large language models (LLMs)—DeepSeek-V4, GPT-5.5, and Gemini 3.5—to clinician-formulated questions regarding polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS). The study found significant differences in performance among the LLMs, with DeepSeek-V4 consistently receiving higher clinician ratings across multiple quality and empathy metrics. Thirty-three distinct English questions, crafted by clinicians and using established PCOS terminology, were submitted to each LLM. Two independent clinicians then rigorously assessed the 99 archived responses using standardized tools such as the DISCERN instrument for information quality, EQIP for transparency, and JAMA benchmarks. Readability was quantitatively analyzed using six different indices, while perceived empathy was subjectively rated. The methodological approach involved matched comparisons using Friedman tests, paired signed-rank permutation comparisons, and Holm correction to account for multiple comparisons.